According to a recent LinkedIn post from C Ray Therapeutics, the Chengdu-based company plans to participate in the ANZSNM2026 conference in Canberra from May 15–17, where it will be present at Booth 48. The post indicates the company is seeking engagement around development partnerships, isotope pilot projects, and clinical collaborations with leading researchers in radiopharmaceuticals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights its positioning as a radiopharmaceutical CRDMO offering services from precursor compound (PCC) selection and pre-clinical evaluation through CMC development, IND filing, clinical supply, and commercial cGMP manufacturing. The post notes a track record of more than 100 CRDMO projects spanning preclinical, investigator-initiated trials, IND-enabling, and clinical stages, including two programs at Phase III.
According to the post, 23 of these projects involve Ac‑225 labeling, underscoring a focus on targeted radiotherapy isotopes alongside broader radioligand work such as Lu‑177. For investors, this emphasis on late-stage and actinium‑based programs may suggest growing capability in high-value radiopharma niches, which could enhance C Ray Therapeutics’ competitiveness as demand for contract development and manufacturing in nuclear medicine continues to expand.
The planned presence at ANZSNM2026 also implies an effort to deepen relationships in the Australia and New Zealand nuclear medicine ecosystem, potentially diversifying the company’s international client base. If successful in converting conference outreach into new development or manufacturing mandates, C Ray Therapeutics could see incremental revenue opportunities and greater visibility within the global radiopharmaceutical supply chain.